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Neuromuscular junctiona b s t r a c t
Low-density lipoprotein receptor-related protein 4 (Lrp4) is essential for pre- and post-synaptic spe-
cialization at the neuromuscular junction (NMJ), an indispensable synapse between a motor nerve
and skeletal muscle. Muscle-speciﬁc receptor tyrosine kinase MuSK must form a complex with
Lrp4 to organize postsynaptic specialization at NMJs. Here, we show that the chaperon Mesdc2 binds
to the intracellular form of Lrp4 and promotes its glycosylation and cell-surface expression. Further-
more, knockdown of Mesdc2 suppresses cell-surface expression of Lrp4, activation of MuSK, and
postsynaptic specialization in muscle cells. These results suggest that Mesdc2 plays an essential role
in NMJ formation by promoting Lrp4 maturation.
Structured summary of protein interactions:
Lrp4 physically interacts with CANX, LRPAP1, CCAR2, MESDC2, PDIA4, RPN1 and SDF2L1 by anti tag
coimmunoprecipitation (View interaction)
Mesdc2 physically interacts with Lrp4 by anti tag coimmunoprecipitation (View interaction)
Mesdc2 physically interacts with Lrp4 by anti bait coimmunoprecipitation (View interaction)
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction receptor-related protein (Lrp) family [3–5]. Prior to motor nerveThe contraction of skeletal muscle is controlled by motor
neurons,whichcontact themuscleﬁbers at theneuromuscular junc-
tion (NMJ), a synapse that uses the neurotransmitter acetylcholine
(ACh) in mammals. For efﬁcient neuromuscular transmission, ACh
receptors (AChRs) must be densely clustered on the postsynaptic
membrane at NMJ [1,2]. The formation of the NMJ is orchestrated
by the muscle-speciﬁc receptor tyrosine kinase MuSK, which forms
a complex with Lrp4, a member of the low-density lipoproteininnervation, MuSK is activated in a manner dependent on its
cytoplasmic activator Dok-7 together with Lrp4, and induces
postsynaptic specialization including AChR clustering in the central
region of muscle [4–7]. After innervation, neural agrin (hereafter
referred to as ‘‘agrin’’), a glycoprotein secreted from presynaptic
nerve terminals, binds to Lrp4 and further upregulates MuSK’s
activity to establish the postsynaptic apparatus of the NMJ [4,5]. In
addition, it was recently reported that Lrp4 interacts with the
motor axon and acts as an important retrograde signal to induce
presynaptic specialization [8,9]. Furthermore, we and others
identiﬁed autoantibodies that recognize the extracellular region of
Lrp4 in patientswithmyasthenia gravis, an autoimmuneneuromus-
cular disease. These antibodies showed inhibitory effects on agrin’s
binding to the cell-surface receptor Lrp4 and subsequent clustering
of AChRs on culturedmyotubes, supporting an essential role for the
agrin-Lrp4 axis in the maintenance of NMJs [10–12]. However, in
contrast to the depth of our understanding of Lrp4 functions, it
remains largely unknown how its function and subcellular
localization are regulated.
In this study, we found that the chaperon protein Mesoderm
development candidate 2 (Mesdc2) binds to Lrp4 and facilitates
3750 T. Hoshi et al. / FEBS Letters 587 (2013) 3749–3754its glycosylation. Moreover, Mesdc2 is a key regulator of
cell-surface expression of Lrp4, activation of MuSK, and consequent
postsynaptic specialization in cultured myotubes. Together, these
ﬁndings suggest an important role for the chaperon in NMJ formation.
2. Materials and methods
2.1. Antibodies and a recombinant protein
Antibodies used in this study were obtained from the
following resources: rabbit monoclonal anti-Lrp4 (Epitomics)
and anti-Mesdc2 (C22F5, for immunoblotting, Cell Signaling);
mouse monoclonal anti-Flag (1E6, for immunoprecipitation and
immunoblotting, Wako; M2, for immunoblotting of immunopre-
cipitated Flag-Mesdc2, Sigma), anti-phosphotyrosine (4G10,
Millipore), and anti-a-Tubulin (DM1A, Santa Cruz); goat
polyclonal anti-Actin (I-19, Santa Cruz), anti-Mesdc2 (AF4545,
for immunoprecipitation, R&D Systems), anti-MuSK (AF562, for
immunoblotting, R&D Systems; N-19 and C-19, 1:1 mixture for
immunoprecipitation, Santa Cruz), and control IgG (Santa Cruz);
and rabbit polyclonal anti-AChR b1 (H-101, Santa Cruz) antibodies.
The recombinant 90 kDa C-terminal fragment of neural agrin was
obtained from R&D Systems.
2.2. Plasmids
The mouse Lrp4 expression plasmids were described previously
[10]. The cDNA encoding Lrp4 with a Flag epitope at its C-terminus
was generated by PCR, and cloned into the pcDNA3.1/myc-His
plasmid (Invitrogen). The mouse Mesdc2 cDNA was cloned by
RT-PCR from poly(A)+ RNA from C2C12 myotubes. The cDNA
encoding Mesdc2, in which a Flag epitope was inserted after the
signal sequence, was generated by PCR, and cloned into
pcDNA3.1/myc-His plasmid. The shRNA sequences for mouse Mes-
dc2 and the non-silencing control are as follows:
Mesdc2 shRNA#1 (target sequence): 50-GCCTGTTGTATCTGTGT-
ATTA-30,
Mesdc2 shRNA#2 (target sequence): 50-TTGTTCAGTGAGTGAA
GATAA-30,
Control shRNA (target sequence): 50-TTCTCCGAACGTGTCACGT-30.
These shRNA sequences were inserted into the pSIREN-RetroQ
plasmid (Takara Bio).
2.3. Cell culture, transfection, tunicamycin treatment, and retrovirus
infection
HEK293T and Plat-E Retroviral packaging cells were cultured in
high glucose Dulbecco’s Modiﬁed Eagle Medium (DMEM) supple-
mented with 10% FBS. C2C12 myoblasts were cultured in DMEM
supplemented with 20% FBS. For differentiation into myotubes,
myoblasts were grown to conﬂuency, and fed with differentiation
medium (DMEM supplemented with 2% horse serum) for 3–5 days.
Expression plasmids were transfected using FuGENE6 (Roche) or
Lipofectamine 2000 (for LC–MS/MS analysis, Invitrogen) according
to themanufacturer’s instruction. For liquid chromatography–tandem
mass spectrometry (LC–MS/MS) analysis, HEK293T cells were
transfected with the expression plasmids of Lrp4-Flag and incu-
bated at 37 C for 24 h. For tunicamycin (TM) treatment, HEK293T
cells were transfected with expression plasmids and incubated at
37 C overnight. The next day, the cells were incubated in the pres-
ence of TM for 16 h. For production of retrovirus, the pSIREN-RetroQ
plasmids were transfected into Plat-E cells. Forty-eight hours after
transfection, the culture medium were collected, ﬁltrated through
a 0.22 lm ﬁlter (Millipore), and administered to C2C12 myoblasts
for infection. Eight hours after infection, the virus-containing
culture medium was removed and the cells were fed withfresh medium and incubated at 37 C overnight. The next day,
puromycin was added to culture media at 1 lg/ml, and the cells
were cultured for an additional 6 days to remove uninfected cells.
2.4. Digestion of Lrp4-binding proteins and LC–MS/MS analysis
HEK293T cells transfected with plasmids expressing Lrp4-Flag
were solubilized in TNE buffer [13]. The lysates were incubated
with mouse monoclonal anti-Flag antibody-conjugated agarose
(M2, Sigma) at 4 C for 1h and subjected to immunoprecipitation.
Lrp4-Flag and co-precipitated proteins were eluted from the slurry
with an excess of Flag peptides, digested with lysyl endopeptidase
C (Wako), and analyzed with a highly sensitive direct nanoﬂow
LC–MS/MS system as previously described [13,14].
2.5. Immunoblotting, immunoprecipitation, and a-bungarotoxin pull-
down
Immunoblotting, immunoprecipitation, and a-bungarotoxin
(a-Btx) pull-down were performed as described previously
[7,15]. To examine phosphorylation of MuSK and AChR, C2C12
myotubes expressing shRNAs were treated with or without agrin
(100pM) at 37 C for 30 min prior to these assays.
2.6. Deglycosylation of Lrp4
The membrane fraction from HEK293T cells transfected with
expression plasmids of Lrp4 was puriﬁed as previously described
[15], and the fraction was denatured at 100 C for 10min in 1
denaturingbuffer (NEB)before incubationwithN-glycosidase F (for re-
moval of Asn-linked glycans, NEB) and/or amixture of Neuraminidase
andO-glycosidase (for removal of Ser/Thr-linkedglycans,NEB) at 37 C
for 3 h in 1 G7 reaction buffer (NEB) supplemented with 1% NP-40.
Reactions were stopped by the addition of Laemmli sample buffer.
2.7. Biotinylation of cell-surface proteins
To label the cell-surface proteins with biotin, cells were washed
with PBS and treated with EZ-link Sulfo-NHS-LC-Biotin (Pierce)
(0.5 mg/ml PBS) at 4 C for 30 min. The reaction was stopped by
two consecutive 20 min treatments with 100 mM Glycine in PBS
at 4 C. NeutrAvidin Agarose Resin (Pierce) and Avidin-HRP
(eBioscience) was used to pull down and detect the biotinylated
cell-surface proteins, respectively, as described elsewhere [16,17].
2.8. AChR clustering assay
Myotubes were treated with or without agrin (10 pM) at 37 C
for 16 h, incubated with Alexa 594-conjugated a-Btx (Invitrogen)
at 37 C for 1 h, and ﬁxed. Fluorescence images of ﬁxed myotubes
were collected with a DM6000B microscope (Leica), and the num-
ber of AChR clusters (>5 lm in their longest diameter) was
counted, as described elsewhere [5,18].2.9. Statistical analysis
All experiments were performed at least 3 times. The quantita-
tive results were expressed as the means ± SEM. Statistical signiﬁ-
cance was determined by the paired t test, unless otherwise noted.
3. Results
3.1. Mesdc2 binds to Lrp4
To gain insights into regulatory mechanisms controlling
Lrp4-mediated signaling, we searched for Lrp4-binding proteins.
Table 1
Identiﬁcation of Mesdc2 as a candidate Lrp4-binding protein by mass spectrometry. Molecular mass to charge ratio (m/z) and charge of each peptide ion observed in LC–MS/MS
analysis together with the assigned amino acid sequence and its position in the corresponding human Mesdc2 protein are shown.
Protein Peptide (m/z) Charge Sequence Residues (start–end)
Mesdc2 794.39 3 DIRDYNDADMARLLEQWEK 54–72
504.55 3 DDDIEEGDLPEHK 73–85
552.28 2 RPSAPVDFSK 86–95
814.41 2 TLMMFVTVSGSPTEK 113–127
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cells, and Lrp4-Flag together with its binding partners were immu-
noprecipitated with anti-Flag antibodies. The immunoprecipitates
were digested and analyzed with a highly sensitive direct nanoﬂow
LC–MS/MS system [13,14]. Following a database search, we identi-
ﬁed peptides apparently derived from 7 candidate binding proteins
(Supplementary Table 1), including four from Mesoderm develop-
ment candidate 2 (Mesdc2) (Table 1). Because binding of overex-
pressed Mesdc2 to other Lrp-family proteins had been reported
[19], we performed a similar test. We immunoprecipitated Flag-
Mesdc2 from the lysates of HEK293T cells transfected with Lrp4
and Flag-Mesdc2 expression plasmids, and conﬁrmed that Lrp4
was co-immunoprecipitated with Flag-Mesdc2 only when both
proteins were expressed (Fig. 1A). Although anti-Lrp4 antibodies
detected two discrete forms with apparent molecular masses of
about 265 and 233 kDa (hereafter referred to as ‘‘upper Lrp4’’
and ‘‘lower Lrp4’’, respectively) (Fig. 1A), lower Lrp4 was selec-
tively co-immunoprecipitated with Flag-Mesdc2 (Fig. 1B). Because
cell-surface receptor proteins are generally glycosylated, we
examined whether the glycosylation status differs between the
two forms of Lrp4 [20]. The membrane fraction prepared
from HEK293T cells expressing exogenous Lrp4 was treated
with N-glycosidase F and/or a mixture of Neuraminidase and
O-glycosidase. Removal of Ser/Thr-linked (O-linked) glycans with
the latter mixture increased the mobility of upper but not lower
Lrp4 (Fig. 1C). On the other hand, treatment with N-glycosidase F
to remove Asn-lined (N-linked) glycans resulted in a mobility shift
of both upper and lower Lrp4 (Fig. 1C). These data indicate that
both forms of Lrp4 are N-glycosylated, and that upper Lrp4 is
further O-glycosylated, aside from glycosylation undetectable in
the assay, if any [21]. We still observed two forms of Lrp4 after
removal of both N- and O-linked glycans, implying that upper
Lrp4 has additional post-translational modiﬁcation(s) (Fig. 1C),
the nature of which is currently unknown. Taken together, these
ﬁndings indicate that Mesdc2 binds to lower Lrp4, which appears
to lack O-linked glycans.Fig. 1. Mesdc2 binds to Lrp4. (A and B) HEK293T cells were transfected with expression
immunoprecipitation (IP) with anti-Flag antibody. The immunoprecipitates andWCL wer
Lrp4 (.) and lower Lrp4 (I) are shown. (C) Membrane fractions of HEK293T cells trans
mixture of Neuraminidase and O-glycosidase. The mobility shift of Lrp4 by deglycosylat3.2. Mesdc2 facilitates glycosylation and cell-surface expression of
Lrp4
Although Mesdc2 binds to lower Lrp4, forced expression of
Mesdc2 appeared to increase upper Lrp4 (Fig. 1A). Therefore, we
evaluated expression levels of upper Lrp4 upon forced expression
of Mesdc2 in HEK293T cells and conﬁrmed signiﬁcantly elevated
expression of upper Lrp4 (Fig. 2A), which is O-glycosylated unlike
lower Lrp4 (Fig. 1C). Because receptor proteins synthesized and
correctly folded in the endoplasmic reticulum are transported to
the Golgi apparatus, where protein O-glycosylation takes place
[22], our ﬁndings suggest that Mesdc2 may facilitate such glycosyl-
ation and trafﬁcking of Lrp4 in the secretory pathway to the cell
surface as a chaperon. Indeed, previous studies suggested a similar
chaperon role for Mesdc2 with two Lrp4-related proteins, Lrp5 and
Lrp6 [19,23]. To test if Mesdc2 chaperons Lrp4, we examined
expression levels of Lrp4 on the cell-surface membrane by treating
HEK293T cells with a membrane-impermeable biotinylation
reagent to speciﬁcally label cell-surface proteins. Co-expression
of Mesdc2 with Lrp4 signiﬁcantly increased cell-surface levels of
the latter (Fig. 2B), supporting a role for Mesdc2 in chaperoning
Lrp4. We also found that upper Lrp4 corresponds to the
cell-surface form with regard to apparent molecular mass,
suggesting that upper Lrp4 is the mature, cell-surface form
(Supplementary Fig. 1). Although we detected a very minor
biotinylated form of Lrp4 with apparently lower molecular mass,
it could be a degradation product of the upper, major, cell-surface
form of Lrp4, or a differently modiﬁed form of it. A fuller
understanding of its molecular nature awaits further studies.
N-linked glycosylation is usually important for appropriate
folding of receptor proteins and subsequent modiﬁcations and
transport to the cell surface [22,24]. To address its contribution
to Lrp4 expression on the surface, we utilized tunicamycin (TM),
a speciﬁc inhibitor of N-linked glycosylation [25]. TM treatment
signiﬁcantly suppressed cell-surface expression of Lrp4, suggesting
that N-linked glycosylation of Lrp4 is essential for its trafﬁcking toplasmids for Lrp4 and/or Flag-Mesdc2. Whole cell lysates (WCL) were subjected to
e subjected to immunoblotting (IB) with the indicated antibodies. Positions of upper
fected with Lrp4 expression plasmids were treated with N-glycosidase F and/or a
ion was analyzed by IB with anti-Lrp4 antibodies.
Fig. 2. Mesdc2 promotes glycosylation and cell-surface expression of Lrp4 in HEK293T cells. HEK293T cells were transfected with expression plasmids for Lrp4 and/or Flag-
Mesdc2, and subjected to the following assays. (A) WCL were subjected to IB with the indicated antibodies (left). Positions of upper Lrp4 (.) and lower Lrp4 (I) are shown.
Ratio of upper Lrp4 to total Lrp4 was quantiﬁed using a chemiluminescence imager (right). The ratio in cells transfected with Lrp4 plasmids alone is arbitrarily deﬁned as 1.0.
Data are expressed as means ± SEM from three independent experiments performed in triplicate. ⁄ Denotes P < 0.05. (B) Cell-surface expression of Lrp4 in transfected
HEK293T cells was analyzed by the biotin-labeling-based quantiﬁcation of cell-surface proteins. The biotinylated cell-surface proteins pulled down (PD) with NeutrAvidin
Agarose and WCL were subjected to IB with the indicated antibodies (left). Ratio of cell-surface Lrp4 to total Lrp4 in HEK293T cells was quantiﬁed (right). The ratio in cells
transfected with Lrp4 plasmids alone is arbitrarily deﬁned as 1.0. Data are shown as means ± SEM. n = 6; ⁄P < 0.05. (C) Transfected HEK293T cells were treated with
tunicamycin (0.1 or 1.0 lg/ml) for 16 h. The cell-surface expression of Lrp4 was analyzed as described above. (D) Transfected HEK293T cells were treated with tunicamycin
(1.0 lg/ml) for 16 h and WCL were subjected to IP with anti-Flag antibody. The immunoprecipitates and WCL were subjected to IB with the indicated antibodies.
Fig. 3. Mesdc2 regulates cell-surface expression of Lrp4 in myotubes. Cell-surface
expression of Lrp4 on the C2C12 myotubes expressing shRNAs against Mesdc2 (#1
and #2) or the control (Ctrl) was analyzed as in Fig. 2B (left). Positions of upper Lrp4
(.) and lower Lrp4 (I) are shown. Ratio of cell-surface Lrp4 to total Lrp4 was
quantiﬁed (right). The ratio in cells expressing the control shRNA is arbitrarily
deﬁned as 1.0. Data are shown as means ± SEM. n = 4; ⁄⁄P < 0.01.
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Lrp4 was not signiﬁcantly affected by the presence of TM (Fig. 2D),
indicating that N-glycosylation of Lrp4 is not a prerequisite for the
binding to Mesdc2. Together, our ﬁndings suggest that Mesdc2
binds to the immature form of Lrp4 to promote its glycosylation
and cell-surface expression.
3.3. Mesdc2 is a key regulator of cell-surface expression of Lrp4, MuSK
activation, and postsynaptic specialization in muscle cells
As mentioned above, the receptor tyrosine kinase MuSK must
form a complex with Lrp4 to orchestrate postsynaptic specializa-
tion at NMJs on myotubes [4–6]. Thus, we examined if Mesdc2
plays a role in cell-surface expression of Lrp4, MuSK activation,and subsequent postsynaptic specialization in cultured myotubes.
To conﬁrm binding of Mesdc2 to lower Lrp4 in these cells, we per-
formed a co-immunoprecipitation assay with myotubes differenti-
ated from C2C12 myoblasts and detected lower Lrp4 in anti-Mesdc2
immunoprecipitates (Supplementary Fig. 2). Thus, we designed
two non-overlapping shRNA sequences against Mesdc2, and
introduced them into C2C12 myoblasts using a retroviral vector.
Infected myoblasts were selected as described in Materials and
methods and differentiated into myotubes, and cell-surface
expression of Lrp4 was evaluated as mentioned. We conﬁrmed
reduced expression of Mesdc2, which strongly inhibited cell-surface
expression of Lrp4 (Fig. 3). Mesdc2 downregulation also reduced
expression levels of upper Lrp4, supporting the idea that it is the
mature, cell-surface form of Lrp4. Next, we tested whether reduc-
tion of Mesdc2 inhibits MuSK activation and subsequent AChR
clustering, both of which are dependent on Lrp4 in myotubes
[4,5]. Indeed, knockdown of Mesdc2 impaired agrin-induced acti-
vation of MuSK, as judged by its autophosphorylation, although
MuSK’s phosphorylation was undetectable in the absence of agrin
irrespectively of the knockdown (Fig. 4A). Moreover, tyrosine phos-
phorylation of AChR, which is triggered on activation of MuSK [26],
was signiﬁcantly suppressed by the downregulation either in the
presence or absence of agrin (Fig. 4B). However, cell-surface
expression of MuSK was not signiﬁcantly affected by the knock-
down of Mesdc2 (Supplementary Fig. 3A). These results indicate
that Mesdc2 plays an essential role in MuSK activation together
with glycosylation and cell-surface expression of Lrp4 in myotu-
bes. Consistently, downregulation of Mesdc2 suppressed AChR
clustering, a characteristic event of MuSK-dependent postsynaptic
specialization, in myotubes (Fig. 4C), although it did not signiﬁ-
cantly affect cell-surface expression of AChR (Supplementary
Fig. 3B). Together, these ﬁndings demonstrate that the chaperon
protein Mesdc2 plays a key role in MuSK-dependent postsynaptic
Fig. 4. Mesdc2 regulates MuSK activation and AChR clustering in myotubes. C2C12 myotubes expressing the indicated shRNAs were treated with or without agrin. (A) WCL
were subjected to IP with anti-MuSK antibodies. The immunoprecipitates and WCL were subjected to IB with the indicated antibodies. pTyr denotes phosphotyrosine.
Positions of MuSK and its tyrosine-phosphorylated form are shown. (B) WCL were incubated with a-Bungarotoxin (a-Btx)-conjugated sepharose to pull down AChR. The
precipitates and WCL were subjected to IB with the indicated antibodies (left). Positions of AChR (b1 subunit) and its tyrosine-phosphorylated form are shown. Ratio of
tyrosine phosphorylated AChR to total AChR b1 was quantiﬁed (right). The ratio in untreated cells expressing the control shRNA is arbitrarily deﬁned as 1.0. Data are shown as
means ± SEM. nP 5; ⁄P < 0.05, ⁄⁄P < 0.01. (C) Myotubes were stained with Alexa594-conjugated a-Btx to visualize AChR clusters (left). Scale bar, 100 lm. The numbers of
AChR clusters per 500 lm myotube length interval (nP 20) were counted (right). Data are expressed as means ± SEM of the numbers from three or more independent
experiments. Statistical signiﬁcance was determined using a Student’s t-test (⁄⁄P < 0.01).
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cell-surface expression of Lrp4 in myotubes.
4. Discussion
In the present study, we demonstrated that Mesdc2 positively
regulates cell-surface expression of Lrp4 and postsynaptic special-
ization in cultured myotubes. Lrp4 forms a complex with MuSK,
binds to motor neuron-derived agrin, and stimulates MuSK’s
kinase activity in cooperation with muscle cytoplasmic protein
Dok-7 [4,5,7]. In addition, Lrp4 binds to the motor axon and
induces presynaptic specialization [8,9]. To exert these activities
essential for neuromuscular synaptogenesis, Lrp4 must be
expressed on the cell-surface membrane of myotubes. Therefore,our ﬁndings suggest that Mesdc2 plays a critical role in NMJ forma-
tion by promoting cell-surface expression of Lrp4. We revealed
that Mesdc2 binds to the less glycosylated, intracellular form of
Lrp4 but not the mature, cell-surface form (Fig. 1B). We also found
that inhibition of N-linked glycosylation prevents cell-surface
expression of Lrp4, but not Lrp4-Mesdc2 binding (Fig. 2C and D).
These ﬁndings suggest that cell-surface expression of Lrp4 requires
both Mesdc2-mediated chaperoning and N-linked glycosylation.
This type of glycosylation plays an important role in the associa-
tion between several glycoproteins and the lectin chaperons Caln-
exin and Calreticulin, which is important for appropriate folding of
their target proteins [20,22]. Because Calnexin was identiﬁed as
one of the potential binding partners of Lrp4 by our LC-MS/MS
analysis (Supplementary Table 1), this lectin chaperon may also
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Mesdc2 regulates cell-surface expression of Lrp4, it was reported
that Mesdc2 prevents protein aggregation and improper disul-
ﬁde-bond formation of Lrp6 [19]. Similar mechanisms may under-
lie Mesdc2-mediated regulation of Lrp4.
In addition to Lrp4, many key NMJ proteins are known to under-
go glycosylation that regulates their activities [27]. For example,
N-linked glycosylation of AChR subunits is required for their
correct folding and cell-surface expression [28]. Recently GFPT1
and DPAGT1, two genes encoding key enzymes for synthesis of an
important building block of N-glycans, were identiﬁed as the caus-
ative genes for certain types of congenital myasthenic syndromes
(CMSs), a group of inherited NMJ disorders [25,29]. Patients with
either GFPT1 or DPAGT1 mutations showed reduced expression
of AChRs in the endplate, which is a region of postsynatic special-
ization on myotubes, suggesting that AChR subunits and/or
regulators of their expression at NMJs are critical targets of these
N-glycosylation-related enzymes. Given that MuSK activation
induces expression of AChR subunits [30,31], N-glycosylation of
Lrp4 might be involved in the pathogenesis of these CMSs.
Furthermore, because Mesdc2 plays a key role in cell-surface
expression of Lrp4 and MuSK-dependent postsynaptic specializa-
tion (Figs. 3 and 4C), it is tempting to speculate that mutations in
MESDC2 might be causally associated with another type of CMS
with impaired NMJ formation.
Like GFPT1 and DPAGT1, Mesdc2 and Lrp4 are expressed in a
wide variety of cell types. Therefore, it would be puzzling if they
function only in NMJs, although NMJs are apparently susceptible
to GFPT1 or DPAGT1 mutations. Indeed, Lrp4 plays essential roles
in various developmental events including bone growth, limb pat-
terning, and kidney formation, probably by regulating Wnt and
BMP signaling [32–34]. Consistently, mutations in the LRP4 gene
were reported as a cause of Cenani–Lenz syndrome, a congenital
distal limb disorder, which is sometimes accompanied by renal
agenesis [33]. Also, LRP4 mutations were reported in patients with
sclerosteosis, characterized by progressive bone overgrowth [34].
Thus, it is important to investigate roles of Mesdc2 not only in
NMJ formation but also in these other developmental events to
understand physiological and pathophysiological roles in the
Mesdc2-mediated regulation of Lrp4.
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